Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Mar 5;127(9):988-96.
doi: 10.1161/CIRCULATIONAHA.112.000682. Epub 2013 Feb 1.

Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis

Affiliations
Randomized Controlled Trial

Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis

Anjali Ganda et al. Circulation. .

Abstract

Background: The number of circulating blood monocytes impacts atherosclerotic lesion size, and in mouse models, elevated levels of high-density lipoprotein cholesterol suppress blood monocyte counts and atherosclerosis. We hypothesized that individuals with mild renal dysfunction at increased cardiovascular risk would have reduced high-density lipoprotein levels, high blood monocyte counts, and accelerated atherosclerosis.

Methods and results: To test whether mild renal dysfunction is associated with an increase in a leukocyte subpopulation rich in monocytes that has a known association with future coronary events, we divided individuals from the Malmö Diet and Cancer study (MDC) into baseline cystatin C quintiles (n=4757). Lower levels of renal function were accompanied by higher monocyte counts, and monocytes were independently associated with carotid bulb intima-media thickness cross-sectionally (P=0.02). Cystatin C levels were positively and plasma high-density lipoprotein cholesterol levels negatively associated with monocyte counts at baseline, after adjustment for traditional risk factors. Several amino acid metabolites tied to low levels of high-density lipoprotein cholesterol and insulin resistance measured in a subset of individuals (n=752) by use of liquid chromatography-mass spectrometry were independently associated with a 22% to 34% increased risk of being in the top quartile of monocytes (P<0.05).

Conclusions: A low high-density lipoprotein cholesterol, insulin resistance phenotype occurs in subjects with mild renal dysfunction and is associated with elevated monocytes and atherosclerosis. High blood monocyte counts may represent a previously unrecognized mechanism underlying the strong relationship between cystatin C and cardiovascular risk.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Drs Gerszten and Wang are named as coinventors on a patent application to the US Patent Office pertaining to metabolite predictors of diabetes mellitus. The remaining authors report no conflicts.

Figures

Figure
Figure
Mild renal dysfunction is linked to a low level of high-density lipoprotein (HDL) cholesterol, a high triglyceride level, and high numbers of monocytes. In cross-sectional analysis of 4662 to 4757 individuals in the cardiovascular cohort of the Malmö Diet and Cancer Study who had available covariate data, lower levels of renal function marked by higher cystatin C concentrations were associated with lower fasting plasma HDL levels (A), higher fasting plasma triglyceride levels (B), and higher monocyte counts (C) (P<0.001 for each, ANOVA). Results are shown as the mean of each variable by cystatin C quintile, with error bars representing the 95% confidence interval (CI). Monocytes were derived by an automatic cell counter 3-part differential method that distinguished cells on the basis of their size (lymphocytes, monocytes plus rare basophils/eosinophils, and neutrophils).

Comment in

References

    1. Yerkey MW, Kernis SJ, Franklin BA, Sandberg KR, McCullough PA. Renal dysfunction and acceleration of coronary disease. Heart. 2004;90:961–966. - PMC - PubMed
    1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305. - PubMed
    1. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and non-traditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities study. J Am Soc Nephrol. 2005;16:529–538. - PubMed
    1. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–2192. - PMC - PubMed
    1. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248. - PubMed

Publication types

MeSH terms

Substances